SCHEMBL302942

SCHEMBL302942

O=C(O)c1ccc(I)o1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38726 0.81 TDP1 (0.61)
SCHEMBL11904537 0.81 TDP1 (0.61)
SCHEMBL18074258 0.78 TDP1 (0.58)
Bromide SCHEMBL20513084 0.78 TDP1 (0.58)
Ammonia Solution, Strong SCHEMBL16240294 0.78 TDP1 (0.58)
SCHEMBL23727166 0.78 TDP1 (0.58)
Fluoride SCHEMBL21331933 0.78 TDP1 (0.58)
Fluoride SCHEMBL20513066 0.78 TDP1 (0.58)
SCHEMBL18074260 0.78 TDP1 (0.58)
Ammonia Solution, Strong SCHEMBL16240292 0.78 TDP1 (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113979974-B Synthesis process of 2, 5-furandicarboxylic acid 上海予君生物科技发展有限公司 2023-07-28 CN claimed
CN-113979974-A Synthesis process of 2, 5-furandicarboxylic acid 上海予君生物科技发展有限公司 2022-01-28 CN claimed
JP-4851440-B2 2012-01-11 JP claimed
CN-101429194-B Process for the preparation of tryptase inhibitors AVENTIS PHARMACEUTICALS, INC. (US) 2011-12-14 CN claimed
EP-1723140-B1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS AVENTIS PHARMA INC (US) 2009-11-04 EP claimed
CN-101429194-A Process for the preparation of tryptase inhibitors AVENTIS PHARMA INC (US) 2009-05-13 CN claimed
US-20070197597-A1 Process for the preparation of tryptase inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-23 US claimed
CN-1950362-A Preparation method of tryptase inhibitor AVENTIS PHARMA INC (US) 2007-04-18 CN claimed
EP-1723140-A1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS Aventis Pharmaceuticals Inc. (US) 2006-11-22 EP claimed
WO-2005095385-A1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2005-10-13 WO claimed
EP-1571150-A1 Process for the preparation of tryptase inhibitors Aventis Pharma Deutschland GmbH (DE) 2005-09-07 EP claimed
US-20230266666-A1 SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-08-24 US disclosed
CN-113979974-B Synthesis process of 2, 5-furandicarboxylic acid 上海予君生物科技发展有限公司 2023-07-28 CN disclosed
CN-113979974-B Synthesis process of 2, 5-furandicarboxylic acid 上海予君生物科技发展有限公司 2023-07-28 CN disclosed
US-20230152691-A1 SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2023-05-18 US disclosed
US-20070197597-A1 Process for the preparation of tryptase inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-23 US disclosed
CN-1950362-A Preparation method of tryptase inhibitor AVENTIS PHARMA INC (US) 2007-04-18 CN disclosed
EP-1723140-A1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS Aventis Pharmaceuticals Inc. (US) 2006-11-22 EP disclosed
WO-2005095385-A1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2005-10-13 WO disclosed
EP-1571150-A1 Process for the preparation of tryptase inhibitors Aventis Pharma Deutschland GmbH (DE) 2005-09-07 EP disclosed